Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107 [0.03%]
阿瑞匹坦（ARQ197）以及联合厄洛替尼治疗乳头状肾细胞癌的平行（随机）Ⅱ期临床试验：SWOG S1107研究
Przemyslaw W Twardowski,Catherine M Tangen,Xiwei Wu et al.
Przemyslaw W Twardowski et al.
Background: Papillary renal cell carcinoma (pRCC) is associated with EGFR expression and activation of MET signaling pathway. A randomized multicenter parallel two-stage phase II trial of MET inhibitor tivantinib alone or...
Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review [0.03%]
肾细胞癌术前系统治疗的手术并发症：系统回顾分析
Barrett McCormick,Matthew A Meissner,Jose A Karam et al.
Barrett McCormick et al.
Background: Locally advanced and metastatic renal cell carcinoma (RCC) is associated with poor survival outcomes. The integration of presurgical systemic therapy with targeted molecular agents prior to surgical resection ...
Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges [0.03%]
抗血管生成和免疫肿瘤药物在转移性肾细胞癌中的影像学应答：现状与未来挑战
Laure Fournier,Alexandre Bellucci,Yann Vano et al.
Laure Fournier et al.
This report aims to review criteria which have been proposed for treatment evaluation in mRCC under anti-angiogenic and immune-oncologic therapies and discuss future challenges for imagers. RECIST criteria seem to only partially reflect the...
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice [0.03%]
非透明细胞肾细胞癌的诊治现状与最佳实践
Meghan Salgia,Jacob Adashek,Paulo Bergerot et al.
Meghan Salgia et al.
The treatment of metastatic renal cell carcinoma (mRCC) has evolved markedly over the past several decades; first with the introduction of targeted therapies and more recently with data supporting checkpoint inhibition. However, the vast ma...
Translating Metabolic Reprogramming into New Targets for Kidney Cancer [0.03%]
代谢重组与肾脏癌新靶点之间的转化关系研究进展
Omran Abu Aboud,Robert H Weiss
Omran Abu Aboud
In the age of bioinformatics and with the advent of high-powered computation over the past decade or so the landscape of biomedical research has become radically altered. Whereas a generation ago, investigators would study their "favorite" ...
Clinical Trials Corner [0.03%]
临床试验版块
Thomas Powles
Thomas Powles
A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma [0.03%]
报告一例VHL突变型晚期肾癌使用纳武单抗后首次给药即发生严重2型乳酸性酸中毒病例
Erica Nakajima,Paul Leger,Ingrid A Mayer et al.
Erica Nakajima et al.
We report a case of severe type B lactic acidosis (LA) in a 51-year-old male, 12 days after he received his first dose of nivolumab for metastatic Von Hippel Lindau (VHL)-mutated, clear cell renal cell carcinoma. Throughout his hospital cou...
Cyllene R Morris,Primo N Lara Jr,Arti Parikh-Patel et al.
Cyllene R Morris et al.
Background and Objective: Since the 1990s, multiple studies have reported on an increased incidence of renal cell carcinomas (RCC), which has been considered incidental to the high use of abdominal diagnostic imaging. This population-based ...
Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden [0.03%]
循环肿瘤DNA（ctDNA）在转移性肾细胞癌（mRCC）中的检测与肿瘤负荷的关系
Manuel Caitano Maia,Paulo Gustavo Bergerot,Nazli Dizman et al.
Manuel Caitano Maia et al.
Background: In a series of 224 patients with advanced renal cell carcinoma (RCC), we have previously reported circulating tumor DNA (ctDNA) detection in 79% of patients. Clinical factors associated with detection are unknown. Methods: Data ...
Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma [0.03%]
系统评价：转移性肾细胞癌的围手术期全身治疗
Patrick G Pilié,Eric Jonasch
Patrick G Pilié
Background: Approximately 16% of patients with renal cell carcinomas (RCC) present with stage IV disease at time of diagnosis. Treatment options for metastatic clear cell RCC, the most common histologic subtype, have proliferated over the p...